Coherus BioSciences Files 8-K on Financials

Ticker: CHRS · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1512762

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: CHRS

TL;DR

CHRS filed an 8-K on March 10th for financial results. Details TBD.

AI Summary

Coherus BioSciences, Inc. filed an 8-K on March 10, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This filing serves as an official notification to investors and the public regarding the company's financial status and operational results, which can influence investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of financial information and does not inherently present new risks.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within this excerpt.

What is the exact date of the earliest event reported?

The date of the earliest event reported is March 10, 2025.

What is the company's principal executive office address?

The address of the principal executive offices is 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.

What is the Standard Industrial Classification code for Coherus BioSciences, Inc.?

The Standard Industrial Classification code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

What was the former name of Coherus BioSciences, Inc.?

The former name of Coherus BioSciences, Inc. was BioGenerics, Inc., with a date of name change on February 10, 2011.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 by Dennis M. Lanfear regarding Coherus BioSciences, Inc. (CHRS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing